Farther Finance Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Farther Finance Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-80	Closed	-$243	–	4455
2024 Q4	$243	Hold	80	–	–	﹤0.01%	3611
2024 Q3	$415	Sell	80 -20	-20%	-$99	﹤0.01%	3468
2024 Q2	$257	Buy	100 +80	+400%	+$273	﹤0.01%	3439
2024 Q1	$95	Sell	20 -5	-20%	-$30	﹤0.01%	3388
2023 Q4	$220	Buy	+25	New	+$205	﹤0.01%	3209

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Farther Finance Advisors's RVNC Position: Q1 2025 in Review

Farther Finance Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 80 shares — an estimated $243 sold.

Farther Finance Advisors first reported a position in RVNC in Q4 2023 and held it in 5 quarters. The position peaked at $415 in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Farther Finance Advisors reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Farther Finance Advisors sold 80 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $243.
Farther Finance Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2023 and held it in 5 quarters.
Farther Finance Advisors's Revance Therapeutics, Inc. position peaked at $415 in Q3 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Farther Finance Advisors's 13F filing for Q1 2025, filed 14 Apr 2025.